Changes in the Updated 2016: WHO Classification of the Myelodysplastic Syndromes and Related Myeloid Neoplasms

    loading  Checking for direct PDF access through Ovid

Abstract

In comparison with the 2008 World Health Organization “Blue Book” on hematopoietic neoplasms, a small number of changes have been made in the classification. In the lower-risk patients, Refractory Cytopenias with Multilineage Dysplasia and Ring Sideroblasts (RCMD-RS) has been separated from RCMD to recognize the importance of the SF3B1 mutation. Often there has been confusion as to the degree of morphologic dysplasia and/or cytopenias to define some of the lower-risk subtypes. In addition, the type of dysplasia or cytopenias is not always concordant. Therefore, it seems prudent to apply the more general term “myelodysplastic syndrome (MDS)” with single- or multiple-lineage dysplasia. Refractory neutropenia or thrombocytopenia has been deemphasized because most patients have multilineage dysplasia. In the higher-risk patients, the terms Refractory Anemia with Excess Blasts (RAEB) 1 or 2 have been simplified to Myelodysplastic Syndrome-Excess Blasts (MDS-EB) 1 or 2 to emphasize the importance of the percentage of blasts that dictate therapy. Patients with Chronic Myelomonocytic Leukemia (CMML) can be classified into 3 groups: CMML 0, 1, or 2, based on the percentage of blasts (< 5%, 5%-9%, 10%-19%). Cases with 50% or more erythroid precursors will not have the percentage of blasts based on the nonerythroid precursors. Previous cases of acute erythroid leukemia (myeloid:erythroid type) can be included in the acute myeloid leukemia (AML) subtype: AML with MDS-related features.

Related Topics

    loading  Loading Related Articles